Cure8 trial brief
Relatives of people with IBD are at higher risk; this study aims to identify early markers or behaviors that predict who develops IBD so prevention or earlier diagnosis might become possible.
First-degree relatives of people with IBD (age ≥14), caregivers of at-risk teens/adults, and researchers studying IBD risk, biomarkers, or the microbiome.
This is a Massachusetts General Hospital observational registry recruiting people age 14 and up who have a parent, sibling, or child with IBD but do not themselves have IBD. Participants are asked to complete yearly questionnaires and provide blood, stool, and urine samples; some parts may be done at home while blood draws occur at the study site.
The study plans to follow participants for about 10 years and will track how many develop IBD, with medical-record confirmation when possible.
The record is an observational, recruiting registry at Massachusetts General Hospital with planned enrollment of ~50 and annual sample/questionnaire collection. It will collect biospecimens and self-reported outcomes, then seek medical records to confirm any IBD diagnoses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
